Scotiabank Starts Travere Therapeutics (TVTX) at Sector Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Price: $49.64 -0.66%
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 16
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 15 | New: 16
Join SI Premium – FREE
Scotiabank analyst Greg Harrison initiates coverage on Travere Therapeutics (NASDAQ: TVTX) with a Sector Outperform rating and a price target of $23.00.
For an analyst ratings summary and ratings history on Travere Therapeutics click here. For more ratings news on Travere Therapeutics click here.
Shares of Travere Therapeutics closed at $17.69 yesterday.
You May Also Be Interested In
- Roth/MKM Starts Dianthus Therapeutics (DNTH) at Buy
- Truist Securities Starts PPL Corp (PPL) at Buy
- Freedom Broker Starts CVR Partners (UAN) at Hold
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
